AdipoGen Life Sciences

iso-Leucettinib-21

Name: iso-Leucettinib-21
Brand: AdipoGen Life Sciences
SKU: AG-MR-C0048
Price: 100.00 CHF
Availability: InStock

As low as CHF 100.00

In stock

Only %1 left

AG-MR-C0048-M0011 mgCHF 100.00

AG-MR-C0048-M0055 mgCHF 330.00

AG-MR-C0048-M02525 mgCHF 980.00

Specifications / Handling

More Information
Product Details
Synonyms	iso-LCTB-21; (R,Z)-6-(Benzo[d]thiazol-5-ylmethylene)-2-((1-methoxy-4-methylpentan-2-yl)amino)-3,5-dihydro-4H-imidazol-4-one
Product Type	Chemical
Properties
Formula	C₁₈H₂₂N₄O₂S
MW	358.5
CAS	3032977-73-1
Purity Chemicals	≥99% (NMR)
Appearance	Pale yellow to off-white powder.
Solubility	Soluble in DMSO (10mM) or ethanol.
Reconstitution	Stock solutions can be made up to 10mM in DMSO.
Identity	Determined by ¹H-NMR.
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry. Protect from light and moisture.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C. Store solutions at -20°C in the dark.
Documents
Safety Data Sheet	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product Description

Kinase inactive isomer of Leucettinib-21 (IC50 DYRK1A > 10 µM). Should be used as a negative control for Leucettinb-21 (Prod. No. AG-MR-C0047).
Does not inhibit the phosphorylation of Tau at Thr212 and cyclin D1 at Thr286, native DYRK1A in HT-22 cells and does not trigger cell apoptotic cell death.
Does not correct cognitive deficits in Ts65Dn model of Down syndrome and other models.

Product-specific References

Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B: E. Deau, et al.; J. Med. Chem. 66, 10694 (2023)
Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate: M.F. Lindberg, et al.; J. Med. Chem. 66, 15648 (2023)
Leucettinib-21, a DYRK1A kinase inhibitor as a clinical drug candidate for Alzheimer’s disease and Down syndrome. In Therapeutic Trials in Alzheimer's Disease: Where Are We Now?: L. Meijer, et al.; J. Alzheim. Dis. (in press) (2024)

Call	+41 61 926 6040
Fax	+41 61 926 6049